QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

Main Article Content

Alhossain A. Khalafallah *
Kristina McDonnell
Hizb U. Dawar
Iain Robertson
David Woods
(*) Corresponding Author:
Alhossain A. Khalafallah | alhossain@yahoo.com

Abstract

Few studies exist that consider health-related quality of life (HR-QOL) in patients with multiple myeloma (MM) undergoing tandem autologous stem cell transplantation (TASCT).

Eighteen patients with advanced MM who underwent dose-modified TASCT were enrolled in this study between March 2006 and March 2008. Patients <60 year old (10) received conditioning with melphalan 140 mg/m2 and patients who were ≥60 years (8) received 100 mg/m2. The median age was 57.5 years (range 35-69). We conducted the European Organization of Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire via interviews at presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health measure improved from 3.44 before transplant to 4.50 (1=very poor, 7=excellent) at the second and subsequent follow-up visits (P<0.001) and the mean global quality of life score improved from 3.61 to 4.71 (P<0.001). Pain symptom was reduced (P=0.001), and physical functioning improved (P<0.001) throughout the period of post-transplant follow-up.

Our study showed that dose-reduced TASCT is well tolerated with low toxicity albeit the transient reduction in QOL during both transplants. Post-transplant follow-up showed significant improvement in overall HR-QOL that reflects positively in the overall disease-outcome.    The EORTC-QLQ-C30 is a practical tool in measuring QOL in myeloma patients.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biography

Alhossain A. Khalafallah, Launceston General Hospital, Tasmania

Department of Haematology and MedicineThe Launceston General HospitalCharles StreetLaunceston, TAS 7250Australia